Even in the presence of serum albumin, EDTA and elevated temperature were required to achieve trans-chelation and restore fluorescence (Figure 1b)
Even in the presence of serum albumin, EDTA and elevated temperature were required to achieve trans-chelation and restore fluorescence (Figure 1b). heart and skin was one-fifth and one-half, respectively, of fluorescence observed with ammonium sulfate-loaded doxorubicin liposomes. After 28 days of twice per week doxorubicin administration of 6 mg/kg, systemic toxicity (cardiac hypertrophy and weight and hair loss) was not detected with the copper-doxorubicin liposomes but was substantial with ammonium sulfate-loaded doxorubicin liposomes. We then incorporated two strategies designed to enhance efficacy, mTOR inhibition (rapamycin) to slow proliferation and therapeutic ultrasound to enhance accumulation and local diffusion. Tumor accumulation was ~10% ID/g and was enhanced approximately two-fold with the addition of therapeutic ultrasound. After the 28-day course of therapy, syngeneic tumors regressed to a pre-malignant phenotype of ~ (1 mm)3or could not be detected. Keywords:Doxorubicin, Liposome, Toxicity, Rapamycin, Ultrasound == Introduction == Effective strategies for low-toxicity, multiply-administered cancer therapies are uncommonly reported1. Encapsulating doxorubicin into liposomes has increased the total tolerated dose24, while cardiac toxicity, mucositis and palmar-plantar erythrodysesthesia restrict the maximum lifetime dose and limit the clinical dosing schedule to 1012 mg/kg/week at intervals of two to six weeks1,5,6. Unexpected synergies between the cardiotoxicities of anthracyclines and growth factors such as anti-ErbB2 antibodies have further increased the need to reduce toxicity7. Given the impact of the dose limitations on efficacy, particles with reduced toxicity would facilitate treatment, particularly in recurrence. To enhance Gabapentin enacarbil stability of doxorubicin within the particle, we create a complex between the drug and a transition metallic, as offers previously been reported for doxorubicin with manganese (II) and irinotecan with copper (II)810. Creation of a copper-doxorubicin complex during the loading process is particularly attractive, since the formation of the copper (II)doxorubicin complex has been associated with oxygen radical-mediated activation of DNA strand scission, the activation of lipid peroxidation mechanisms and resultant Gabapentin enacarbil toxicities1113. Formation of a drug-metal complex during loading changes the morphology of the liposomes and consequently improves circulation lifetime and the build up of liposomes in tumors14,15. Further, a 1:2 complex of copper and doxorubicin having a stability constant of 1016forms when a neutral pH is created within liposomes16,17. Yet, at a low pH, such as the pH experienced within a lysosome or tumor, the stable copper: doxorubicin percentage has been reported to change to 1 1:1 and the stability of the complex decreases17. Here, we track the liposome shell using positron emission tomography (PET) and the drug using multi-spectral fluorescence in order to assess the pharmacokinetics. Further, the protecting covering of liposomes reduces drug diffusion within the tumor, and the effect of liposomal therapy on medical effectiveness has been moderate18. We address the dual issues of toxicity and effectiveness by applying our stable particle in an aggressive dosing routine and incorporating two strategies designed to enhance effectiveness: mTOR inhibition to sluggish proliferation19and restorative ultrasound to enhance build up and local diffusion20,21. The aggressive syngeneic Met-1 model is known to be sensitive to rapamycin (which is an mTOR inhibitor); however, rapamycin only is not curative with this model22. Ultrasound, like a source of thermal and mechanical energy can augment drug delivery by liberating the drug or increasing vascular permeability and thus particle build up and diffusion20,21. Tumor blood vessels present relatively permeable capillaries that allow macromolecules and small liposomes (100 nm) to leak through open gaps and fenestration due to the enhanced permeability and retention (EPR) effect23,24. Heating of the tumor rim, when combined with liposomal medicines, can enhance restorative effectiveness as was previously shown for radiofrequency (RF) ablation combined with liposomal doxorubicin25. Therefore, by enhancing the pharmacokinetic profile and the extent of the EPR effect, we demonstrate enhanced effectiveness and reduced toxicity in a highly aggressive mouse model of breast malignancy26,27. == Materials and Methods == A detailed description of the experimental methods is found in theSupplementary Info. == Liposomes and drug preparation == Doxil (Ortho Biotech Products, LP Raritan, NJ), a commercial ammonium sulfate-loaded doxorubicin liposome, is used for assessment to experimental preparations. Long-circulating liposomes (LCLs) prepared from HSPC:chol:DSPE-PEG2k (56:39:5), the lipid composition of Doxil, were used in this study28. == Copper liposome preparation == Liposomes were prepared as explained in29. L–phosphatidylcholine, hydrogenated soy (HSPC), 1,2 distearoyl-sn-glycero-3-phosphoethanolamine-N-Methoxy polyethyleneglycol-2000 (DSPE-PEG2k), F2rl1 1,2-dipalmitoyl-sn-glycero-3-phospho-choline (DPPC), and 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) were purchased from Avanti Polar Lipids Inc. (Alabaster, Gabapentin enacarbil AL). The dried lipid was hydrated in 0.3 ml of 100 mM copper (II) gluconate (PURAC, Lincolnshire, IL) including 270 mM triethanolamine (TEA, Sigma, St. Louis, MO), pH 7.4 unless otherwise stated. The multi-lamellar lipid answer at a final concentration of 50 mg/mL was extruded above the phase transition temperature of the lipid combination through a polycarbonate membrane having a pore diameter of 100 nm. Copper/TEA-loaded liposomes were then separated from non-encapsulated copper/TEA by moving the extruded liposomal answer through a spin column of Sephadex G-75 (5 1 cm, GE Healthcare, Biosciences, Piscataway, NJ).